JP7023243B2 - イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法 - Google Patents

イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法 Download PDF

Info

Publication number
JP7023243B2
JP7023243B2 JP2018556921A JP2018556921A JP7023243B2 JP 7023243 B2 JP7023243 B2 JP 7023243B2 JP 2018556921 A JP2018556921 A JP 2018556921A JP 2018556921 A JP2018556921 A JP 2018556921A JP 7023243 B2 JP7023243 B2 JP 7023243B2
Authority
JP
Japan
Prior art keywords
isoquinoline
methyl
carboxamide
piperidine
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556921A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515931A (ja
JP2019515931A5 (de
Inventor
スニル クマール ケーシー
ゴピ クマール ミッタパリ
ブライアン ジョゼフ ホフィレナ
ジョゼフ ティモシー マラコビッツ
チャンドラモーリ チルタ
チ チン マック
ジャングオ カオ
Original Assignee
サミュメッド リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サミュメッド リミテッド ライアビリティ カンパニー filed Critical サミュメッド リミテッド ライアビリティ カンパニー
Publication of JP2019515931A publication Critical patent/JP2019515931A/ja
Publication of JP2019515931A5 publication Critical patent/JP2019515931A5/ja
Application granted granted Critical
Publication of JP7023243B2 publication Critical patent/JP7023243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018556921A 2016-04-27 2017-04-27 イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法 Active JP7023243B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328210P 2016-04-27 2016-04-27
US62/328,210 2016-04-27
PCT/US2017/029797 WO2017189823A2 (en) 2016-04-27 2017-04-27 Isoquinolin-3-yl carboxamides and preparation and use thereof

Publications (3)

Publication Number Publication Date
JP2019515931A JP2019515931A (ja) 2019-06-13
JP2019515931A5 JP2019515931A5 (de) 2021-03-25
JP7023243B2 true JP7023243B2 (ja) 2022-02-21

Family

ID=60157342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556921A Active JP7023243B2 (ja) 2016-04-27 2017-04-27 イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法

Country Status (19)

Country Link
US (5) US10508099B2 (de)
EP (2) EP3943086A1 (de)
JP (1) JP7023243B2 (de)
KR (1) KR102399206B1 (de)
CN (1) CN109311819B (de)
AR (1) AR108326A1 (de)
AU (1) AU2017258187B2 (de)
BR (1) BR112018072190A2 (de)
CA (1) CA3022044A1 (de)
CL (2) CL2018003050A1 (de)
CO (1) CO2018012655A2 (de)
IL (1) IL262495B (de)
MA (1) MA43605B1 (de)
MX (1) MX2018013173A (de)
PE (1) PE20190260A1 (de)
PH (1) PH12018502259A1 (de)
RU (1) RU2018141379A (de)
SG (2) SG10201914127PA (de)
WO (1) WO2017189823A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
PE20200008A1 (es) 2017-03-30 2020-01-06 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
US11149022B2 (en) * 2017-10-17 2021-10-19 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019084497A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL AND ARYL WITH 6 CHAINS) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
WO2019084496A1 (en) 2017-10-27 2019-05-02 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
EP3807261B1 (de) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl-pyrazole als modulatoren von roryt
WO2019243999A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
CN112292183A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的6-氨基吡啶-3-基吡唑
WO2019244000A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
TW202024053A (zh) * 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
AU2020343737A1 (en) * 2019-09-05 2022-03-31 Lunan Pharmaceutical Group Corporation MAGL inhibitor, preparation method therefor and use thereof
JP2023549682A (ja) * 2020-10-29 2023-11-29 メルク・シャープ・アンド・ドーム・エルエルシー Ｌｒｒｋ２阻害薬としてのｎ－結合イソキノリンアミド、医薬組成物及びその使用
EP4294798A1 (de) * 2021-02-19 2023-12-27 Kalvista Pharmaceuticals Limited Faktor xiia-hemmer
WO2023055679A1 (en) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc C-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20240133695A (ko) * 2021-12-10 2024-09-04 프로테나 바이오사이언시즈 리미티드 Dyrk1a 억제제로서의 헤테로시클릭 화합물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
JP2010536752A (ja) 2007-08-15 2010-12-02 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
JP2013501792A (ja) 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
JP2013523715A (ja) 2010-03-31 2013-06-17 アクテリオン ファーマシューティカルズ リミテッド イソキノリン−３−イル尿素誘導体
JP2014526510A (ja) 2011-09-14 2014-10-06 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−３−カルボキサミドおよびＷＮＴ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2131463B1 (es) * 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CN102595900B (zh) 2009-08-10 2015-07-15 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
AR084280A1 (es) 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
US9557993B2 (en) 2012-10-23 2017-01-31 Analog Devices Global Processor architecture and method for simplifying programming single instruction, multiple data within a register
EP3119393A4 (de) 2014-03-20 2018-02-28 Samumed, LLC 5-substituierte indazol-3-carboxamide und herstellung und verwendung davon
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2020006115A1 (en) 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
JP2010536752A (ja) 2007-08-15 2010-12-02 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
JP2013501792A (ja) 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
JP2013523715A (ja) 2010-03-31 2013-06-17 アクテリオン ファーマシューティカルズ リミテッド イソキノリン−３−イル尿素誘導体
JP2014526510A (ja) 2011-09-14 2014-10-06 サミュメッド リミテッド ライアビリティ カンパニー インダゾール−３−カルボキサミドおよびＷＮＴ／β−カテニンシグナル伝達経路阻害剤としてのそれらの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mallinger, Aurelie，2,8-disubstituted-1,6-naphthyridines and 4,6-disubstituted-isoquinolines with potent, selective affinity for CDK8/19，ACS Medicinal Chemistry Letters ，2016年，7(6)，573-578
Wu, Jing-Fang，Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461，Bioorganic & Medicinal Chemistry Letters ，2015年，25(16)，3251-3255

Also Published As

Publication number Publication date
CA3022044A1 (en) 2017-11-02
MA43605A1 (fr) 2020-04-30
SG10201914127PA (en) 2020-02-27
IL262495A (en) 2018-12-31
CO2018012655A2 (es) 2019-04-30
CL2018003050A1 (es) 2019-01-25
KR20190012167A (ko) 2019-02-08
BR112018072190A2 (pt) 2019-02-12
KR102399206B1 (ko) 2022-05-17
CN109311819A (zh) 2019-02-05
US10556885B2 (en) 2020-02-11
SG11201809310PA (en) 2018-11-29
US20170313681A1 (en) 2017-11-02
WO2017189823A2 (en) 2017-11-02
MX2018013173A (es) 2019-02-13
IL262495B (en) 2021-12-01
RU2018141379A3 (de) 2020-08-13
AR108326A1 (es) 2018-08-08
US10287267B2 (en) 2019-05-14
JP2019515931A (ja) 2019-06-13
PH12018502259A1 (en) 2019-06-10
CL2019002067A1 (es) 2020-07-10
AU2017258187B2 (en) 2021-08-26
EP3448838B1 (de) 2021-08-11
RU2018141379A (ru) 2020-05-28
US10508099B2 (en) 2019-12-17
US20180208580A1 (en) 2018-07-26
US20200339536A1 (en) 2020-10-29
US20180222887A1 (en) 2018-08-09
MA43605B1 (fr) 2020-10-28
US11174244B2 (en) 2021-11-16
PE20190260A1 (es) 2019-02-25
US20230104155A1 (en) 2023-04-06
EP3448838A2 (de) 2019-03-06
CN109311819B (zh) 2022-10-25
AU2017258187A1 (en) 2018-11-15
WO2017189823A3 (en) 2018-02-08
EP3943086A1 (de) 2022-01-26
US11673881B2 (en) 2023-06-13
EP3448838A4 (de) 2019-12-25

Similar Documents

Publication Publication Date Title
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
JP6993985B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
JP6586104B2 (ja) ５−置換インダゾール−３−カルボキサミドならびにその調製および使用の方法
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN102203067B (zh) Hedgehog通路调节剂
JP5832524B2 (ja) ピリドン及びアザピリドン化合物、並びにそれらの使用方法
US10604514B2 (en) 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
KR20180052640A (ko) 퀴놀론계를 대체하는 유도체 또는 그의 약학적으로 수용가능한 염 또는 입체이성체 및 이들의 의약용 조성물과 응용
JP7369132B2 (ja) ５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法
WO2018127195A1 (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2022199662A1 (zh) 一种多环化合物及其应用
WO2019084496A1 (en) 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL- (HETEROARYL 5-CHAIN) CARBOXAMIDES, PREPARATION AND USE
CN104822658A (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
RU2775505C2 (ru) Изохинолин-3-иловые карбоксамиды и их получение и применение
TWI673268B (zh) 作為ｆｇｆｒ４抑制劑之稠環雙環吡啶基衍生物
BR112018072169B1 (pt) Compostos isoquinolin-3-il carboxamidas, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220208

R150 Certificate of patent or registration of utility model

Ref document number: 7023243

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113